| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Biochemistry and Molecular Biology, University of Illinois, Chicago, IL 60612;
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; and
Committee on Immunology, Department of Pathology, Ben May Institute for Cancer Research, University of Chicago, Chicago, IL 60637
B7-1 (CD80)-transfected P815 tumor cells were previously shown to elicit tumor-eradicating immunity that leads to the regression of B7-1+ P815 tumors after transient growth in normal syngeneic (DBA/2) mice. Here, we show that not only the B7-1 molecule but also the B7-2 (CD86) molecule contributed to the eradication of B7-1+ P815 tumors. The B7-1 molecule that contributed to the eradication of B7-1+ P815 tumors was expressed not only on the tumor cells but also on host APCs, including MAC-1+ cells. The B7-2 molecule that contributed to the eradication of B7-1+ P815 tumors was expressed only on host APCs, such as B220+ cells, and not on the tumor cells. In spite of the fact that B7-expressing host APCs contributed to the eradication of B7-1+ P815 tumors, only CD8+ T cells without help from CD4+ T cells were important for tumor eradication. Taken together, these findings indicate that in addition to the ability of B7-1-transfected tumor cells to stimulate CD8+ T cell-mediated tumor-eradicating immunity directly, such tumor cells can also stimulate CD8+ T cell-mediated tumor-eradicating immunity indirectly as a result of cross-priming through B7-expressing host APCs.
This article has been cited by other articles:
|
|
 |
|
  M. G. Petroff, L. Chen, T. A. Phillips, D. Azzola, P. Sedlmayr, and J. S. Hunt B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface Biol Reprod, May 1, 2003; 68(5): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Murphy, R. Holtz, N. Lewandowski, T. B. Tomasi, and H. Fuji DNA Alkylating Agents Alleviate Silencing of Class II Transactivator Gene Expression in L1210 Lymphoma Cells J. Immunol., September 15, 2002; 169(6): 3085 - 3093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. LaBelle, C. A. Hanke, B. R. Blazar, and R. L. Truitt Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia Blood, March 15, 2002; 99(6): 2146 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Donepudi, P. Raychaudhuri, J. A. Bluestone, and M. B. Mokyr Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells J. Immunol., June 1, 2001; 166(11): 6491 - 6499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL J. Immunol., May 1, 2001; 166(9): 5557 - 5566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, A. J. Corbett, J. L. Brady, R. M. Sutherland, and A. M. Lew CD4 Help-Independent Induction of Cytotoxic CD8 Cells to Allogeneic P815 Tumor Cells Is Absolutely Dependent on Costimulation J. Immunol., October 1, 2000; 165(7): 3612 - 3619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Sojka, M. Donepudi, J. A. Bluestone, and M. B. Mokyr Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells J. Immunol., June 15, 2000; 164(12): 6230 - 6236. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
